Clarest Health’s Post

340B can be a powerful tool for healthcare equity by creating a ripple effect where drug savings for safety-net providers translate into expanded services and healthier communities. As technology to manage drug discounts bridges the gap between 340B and even MDRP, a more streamlined system could be effective in unlocking the program's full potential, allowing cost savings to flow directly to patients and fuel further progress in affordable care. #340B #Healthcare #MDRP

Great Article on Buy and Bill for those looking to build their skill set.

Exploring the Ins and Outs of Buy-and-Bill: A Deep Dive into Provider-Administered Drugs. Our latest blog covers everything from the basics to best practices, offering valuable insights for healthcare providers and payers alike: https://lnkd.in/eE-_8_r4 #Healthcare #BuyAndBill #SpecialtyDrugs #PACS

🌐 #GlobalBiosimilarsWeek shines a spotlight on biosimilars' potential to revolutionize health care access. Part 2 of this insightful series delves into the complex web of payer and pharmacy benefit managers (PBM) policies that impact biosimilar access, from formulary placements to cost-sharing dynamics. Biosimilars offer vital cost savings, yet PBM and payer policies often create barriers, favoring originators due to rebate structures. Addressing these policy issues—whether through transparency or reform—could open doors to more affordable health care for patients nationwide. Let's work towards a biosimilar-friendly future that prioritizes accessibility and affordability! https://lnkd.in/eMF7Hi2q

🚨 𝐁𝐑𝐄𝐀𝐊𝐈𝐍𝐆 𝐍𝐄𝐖𝐒: 𝐀𝐂𝐂𝐎𝐔𝐍𝐓𝐀𝐁𝐈𝐋𝐈𝐓𝐘 𝐈𝐍 𝐏𝐁𝐌 𝐈𝐍𝐃𝐔𝐒𝐓𝐑𝐘🚨 The recent hearing announced by Chairman Comer sheds light on the significant role that Pharmacy Benefit Managers (PBMs) play in the escalating costs of healthcare. As highlighted, the lack of transparency and the complex business practices of traditional PBMs contribute to higher drug prices and limited access to affordable medications for patients. 𝐓𝐮𝐧𝐞 𝐢𝐧 𝐭𝐨 𝐰𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐚𝐧𝐝 𝐥𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐡𝐨𝐰 𝐭𝐡𝐞𝐬𝐞 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞𝐬 𝐚𝐫𝐞 𝐢𝐦𝐩𝐚𝐜𝐭𝐢𝐧𝐠 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐜𝐨𝐬𝐭𝐬! At AffirmedRx, we were founded on the principle of breaking away from these traditional, opaque practices. We believe in full transparency in our pricing and business model, ensuring that our clients and members always know exactly what they are paying for. Our commitment is to provide clear, honest, and straightforward pharmacy benefits management, focused on public good rather than profit margins. We are dedicated to combating the corruption and lack of transparency seen in the industry. Our approach is different – we prioritize our clients’ needs, ensuring they receive the most cost-effective and efficient solutions without hidden fees or misleading practices. Join us in our mission to transform the PBM industry and make healthcare more affordable for everyone. 𝐑𝐞𝐚𝐜𝐡 𝐨𝐮𝐭 𝐭𝐨 𝐀𝐟𝐟𝐢𝐫𝐦𝐞𝐝𝐑𝐱 𝐭𝐨𝐝𝐚𝐲 𝐭𝐨 𝐟𝐢𝐧𝐝 𝐨𝐮𝐭 𝐡𝐨𝐰 𝐰𝐞 𝐝𝐨 𝐭𝐡𝐢𝐧𝐠𝐬 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐥𝐲 𝐚𝐧𝐝 𝐡𝐨𝐰 𝐰𝐞 𝐜𝐚𝐧 𝐡𝐞𝐥𝐩 𝐲𝐨𝐮 𝐚𝐜𝐡𝐢𝐞𝐯𝐞 𝐛𝐞𝐭𝐭𝐞𝐫, 𝐦𝐨𝐫𝐞 𝐚𝐟𝐟𝐨𝐫𝐝𝐚𝐛𝐥𝐞 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞. #HealthcareTransparency #PBM #PharmacyBenefits #AffirmedRx #Accountability https://lnkd.in/eK-EKN7a

CMS Tackles Generic Drug Costs. The Centers for Medicare & Medicaid Services (CMS) has introduced a proposed list of generic drugs aimed at reducing cost-sharing burdens for patients. This initiative could significantly lower the out-of-pocket costs for essential medications. Key takeaways:  💠Reduced costs for essential generics  💠Potential positive impact on patient care    💠More equitable access to critical medications Want to know more about how this proposal could change healthcare? Check out the full article: https://lnkd.in/eEu8qwHJ #generics #Healthcare  #medicare #medicine #pharma

This article does make some valid points about 340B, but there are many things it fails to consider. ❌ Myth: Patients don't benefit from 340B discounts. ✅ Fact: While there's room for improvement in accessibility, countless patients rely on the reduced prices facilitated by 340B to access essential medications. These discounts DO make a tangible difference in affordability for many. ❌ Myth: Contract pharmacies aren't integral to the program. ✅ Fact: The evolution of contract pharmacies has expanded access to 340B medications, particularly in underserved areas. This growth represents progress in reaching those who need assistance the most to ensure no one is left behind. ❌ Myth: Transparency is lacking in 340B transactions. ✅ Fact: Efforts to enhance transparency are ongoing, but let's not overlook the core mission of 340B: to support healthcare providers serving vulnerable populations. The 340B program has made strides in expanding access to vital medications and healthcare services. There's always room for improvement, but let's not lose sight of the countless lives positively impacted by this essential initiative. #340B #Healthcare #Medications

In this week's edition of Health Care Week in Review, my healthcare colleagues discuss #HHS' newly released final guidance for the second cycle of Medicare drug price negotiations, #CMS' release of the 2026 Notice of Benefit and Payment Parameters proposed rule, and more. #healthlaw

Enable Continuous Improvement in Healthcare with the agile BPAMedical365®, https://lnkd.in/e7yDVY7R ☯ A brief guide on how to measure quality improvement in healthcare, https://lnkd.in/dBhnnCfu #healthcare #medtech #pharma #patientsafety #iso13485 #eQMS #qualitymanagement

#PBMReform #FixPriorAuth If you enjoyed the Federal Trade Commission report on PBMs, you’ll also appreciate the report from House Committee on Oversight and Government Reform - continuing to turn up the heat! But really, how many more reports do we need? It’s time for action and legislation! “The three largest PBMs have used their position as middlemen and integration with health insurers, pharmacies, providers, and recently manufacturers, to enact anticompetitive policies and protect their bottom line.” “PBMs frequently tout the savings they provide for payers and patients through negotiation, drug utilization programs, and spread pricing, even though evidence indicates that these schemes often increase costs for patients and payers.” “The largest PBMs’ use of tools such as prior authorizations, fail first policies, and formulary manipulations have significant detrimental impacts on Americans’ health outcomes.” https://lnkd.in/gWD7g2iY